Catalase Inhibitors with Dual Pro‐Oxidant Effect as New Therapeutic Agents in Castration‐Resistant Prostate Cancer
- 16 December 2020
- journal article
- research article
- Published by Wiley in Advanced Therapeutics
- Vol. 4 (3)
Abstract
Almost all patients with advanced prostate cancer (PCa) will eventually progress to incurable castration‐resistant PCa (CRPC) if endocrine therapy fails. Therefore, identifying potential cellular targets is critical for the development of novel and effective treatments for CRPC. Based on the investigation of the molecular mechanism of ATN‐224, an anticancer drug in clinical trials, in CRPC DU145 cells, the antioxidant enzyme catalase (CAT) has been recognized as an actionable CRPC therapeutic target, and the modulation of intracellular redox state through CAT inhibition has great potential for CRPC treatment. After systematic design and synthesis, the benzaldehyde thiosemicarbazone derivative BT‐1 is shown to be effective CAT inhibitor in DU145 cells. This inhibition induces the significant increase of both superoxides (O 2 •− ) and H 2 O 2 levels in DU145 cells. Finally, the dual pro‐oxidant effect of BT‐1 is demonstrated to lead to apoptosis as well as cell‐cycle arrest in DU145 cells, effectively reducing CRPC tumors.Keywords
Funding Information
- National Key Research and Development Program of China (2017YFA0505203)
- National Natural Science Foundation of China (21877045)
This publication has 58 references indexed in Scilit:
- Reactive Oxygen Species Production in the Phagosome: Impact on Antigen Presentation in Dendritic CellsAntioxidants & Redox Signaling, 2013
- Distinct Redox Profiles of Selected Human Prostate Carcinoma Cell Lines: Implications for Rational Design of Redox TherapyCancers, 2011
- Immunotherapy for Urothelial Carcinoma: Current Status and PerspectivesCancers, 2011
- Novel agents and new therapeutics in castration-resistant prostate cancerCurrent Opinion in Oncology, 2011
- Emerging novel therapies in the treatment of castrate-resistant prostate cancerCanadian Urological Association Journal, 2011
- Ferroportin and Iron Regulation in Breast Cancer Progression and PrognosisScience Translational Medicine, 2010
- Oxidative stress in prostate cancerCancer Letters, 2009
- Effects of Manganese Superoxide Dismutase Silencing on Androgen Receptor Function and Gene Regulation: Implications for Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Superoxide dismutase 1 (SOD1) is essential for H 2 O 2 -mediated oxidation and inactivation of phosphatases in growth factor signalingProceedings of the National Academy of Sciences, 2008
- Measuring reactive species and oxidative damagein vivoand in cell culture: how should you do it and what do the results mean?British Journal of Pharmacology, 2004